Seelos Therapeutics (SEEL) Stock Price, News & Analysis

-0.01 (-2.98%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
203,694 shs
Average Volume
428,540 shs
Market Capitalization
$4.46 million
P/E Ratio
Dividend Yield
Price Target

Seelos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
21,392.2% Upside
$70.00 Price Target
Short Interest
5.82% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

SEEL stock logo

About Seelos Therapeutics Stock (NASDAQ:SEEL)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

SEEL Stock Price History

SEEL Stock News Headlines

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Nasdaq Down 100 Points; US Housing Starts Surge In February
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Seelos Therapeutics Inc.
Seelos Therapeutics, Inc. (SEEL)
Seelos Therapeutics Inc SEEL
See More Headlines
Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$2.20 million
Book Value
($3.42) per share


Free Float
Market Cap
$4.46 million

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Raj Mehra J.D. (Age 63)
    Ph.D., Founder, Chairman, CEO & President
    Comp: $599.53k
  • Mr. Michael J. Golembiewski (Age 52)
    Chief Financial Officer
    Comp: $388.2k
  • Ms. Kimberly Farrand
    Senior Director of Clinical Development & Operations
  • Mr. Anthony Marciano
    Chief Communications Officer
  • Gopal Krishna Ph.D.
    Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D.
    Chief Medical Officer
  • Ms. Karen Fusaro
    Senior VP & Head of Clinical Operations

SEEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Seelos Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares.
View SEEL analyst ratings
or view top-rated stocks.

What is Seelos Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12 month price objectives for Seelos Therapeutics' stock. Their SEEL share price targets range from $30.00 to $120.00. On average, they anticipate the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 21,392.2% from the stock's current price.
View analysts price targets for SEEL
or view top-rated stocks among Wall Street analysts.

How have SEEL shares performed in 2024?

Seelos Therapeutics' stock was trading at $1.39 at the beginning of 2024. Since then, SEEL shares have decreased by 76.6% and is now trading at $0.3257.
View the best growth stocks for 2024 here

When is Seelos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SEEL earnings forecast

What ETF holds Seelos Therapeutics' stock?

AdvisorShares Psychedelics ETF holds 513,330 shares of SEEL stock, representing 3.32% of its portfolio.

When did Seelos Therapeutics' stock split?

Shares of Seelos Therapeutics reverse split before market open on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

How do I buy shares of Seelos Therapeutics?

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SEEL) was last updated on 4/23/2024 by Staff

From Our Partners